Clinical trial NCT06069297: Prehabilitation in Pancreatic Surgery
Official title: Multimodal Prehabilitation in Localized Pancreatic Cancer Patients Undergoing Surgery: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pancreatic Cancer
Periampullary Cancer
Frailty Syndrome
Malnutrition
Perioperative/Postoperative Complications
Keywords: Prehabilitation
Physical function
Nutritional status
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
Collaborators: name: Ministry of Health, Italy
First posted: 2023-10-05
Enrollment: 226
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Enrolled patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation) or to the usual care group
Primary purpose: PREVENTION

Brief summary: In patients with pancreatic cancer, older age, multiple comorbidities, frailty, malnutrition and poor functional status are common, especially in individuals receiving neoadjuvant chemotherapy. These characteristics represent potentially modifiable risk factors for poor postoperative outcomes.

The goal of this clinical randomized controlled trial is to evaluate the extent to which a four-week multimodal prehabilitation program impacts on postoperative morbidity, functional and nutritional status and health-related quality of life in patients with localized pancreatic or periampullary cancer scheduled for curative surgery.

In addition, the impact of prehabilitation on circulating sarcopenia and cancer cachexia biomarkers in PDAC patients will be explored.

Included patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation), which will receive prehabilitation, or to the control group, which will receive no prehabilitation.

Detailed description: BACKGROUND:

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, with 5-year survival around 10%. The combination of surgical resection and chemotherapy represents the most efficacious therapy to improve prognosis for localized PDAC. Patients with pancreatic cancer are generally older adults in whom frailty, sarcopenia and/or malnutrition are common. These features have all been associated with poor postoperative complications and reduced survival. Therefore, the preoperative period and the time window after the end of chemotherapy constitute a unique opportunity to condition modifiable risk factors, improve functional capacity and address deficiencies in physiologic reserves, which might otherwise preclude surgery or significantly impede recovery.

Prehabilitation is defined as the process of enhancing patients' functional capacity to enable them to withstand a stressful event. Multimodal prehabilitation, which defines a program including physical, nutritional, and psychological interventions, has shown the most promising results in gastrointestinal cancer surgery. However, no high-quality evidence is currently available for PDAC patients.

STUDY OBJECTIVES:

Primary Aim: to evaluate if a 4-week multimodal structured prehabilitation program including physical exercise, nutritional and psychological interventions will result in a clinically significant increase in functional capacity, nutritional status and patient-reported health-related quality of life before surgery when compared to a usual care control group, and evaluate the extent to which multimodal prehabilitation impacts on postoperative morbidity and patient recovery compared to usual care.

Secondary Aim: to analyze whether multimodal prehabilitation may impact on the concentration and activity of a panel of specific circulating molecules involved in cancer cachexia and skeletal muscle wasting, chronic inflammation.

STUDY DESIGN:

A randomized controlled trial will be performed in PDAC and periampullary cancer patients with indication to upfront pancreatic resection or pancreatic resection after completion of neoadjuvant chemotherapy.

Included patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation), which will receive prehabilitation, or to the control group, which will receive no prehabilitation. All patients will receive the same intraoperative and postoperative care based on an established enhanced recovery pathway.

Inclusion and exclusion criteria as stated in the eligibility section will be assessed and patients consented to participate in the study if they fulfill inclusion criteria.

RANDOMIZATION AND BLINDING:

The trial is designed as a randomized, controlled, assessor-blind trial. Participants will be randomly assigned to either multimodal prehabilitation or no prehabilitation group with a 1:1 allocation using permuted blocks of random sizes. Randomization will be stratified by neoadjuvant chemotherapy and tumor location (periampullary or pancreatic head-neck cancer versus pancreatic body-tail cancer). Allocation concealment will be ensured as the randomization code will not be released until the patient has been recruited into the trial, which takes place after all baseline measurements have been completed and informed consent has been signed.

PREOPERATIVE ASSESSMENT:

All patients will be evaluated at baseline (T0) by:

* Patient medical history including comorbidities, presence of signs or symptoms, and frailty assessment using Fried's criteria.
* Physical performance tests including functional walking capacity (six-minute walk test), timed up and go test, gait speed assessment and handgrip strength test.
* Assessment of nutritional status by nutrition history, measurement of anthropometric parameters, completion of nutritional screening questionnaires (MNA, PG-SGA), and standard biochemical markers of malnutrition and inflammation including albumin, prealbumin, total lymphocyte count, and C-reactive protein.
* Body composition measurements assessed using two methods:

  * multi-frequency bioelectrical impedance analysis (BIA) providing data on extracellular and intracellular water as % of total body water, fat mass (FM) as % of body weight, skeletal muscle mass (SK) as % of fat-free mass (FFM) and phase angle (PA°), intramuscular fat mass (IMAT), basal metabolic rate (BMR) energy expenditure and hypotalamic- pituitary- adrenal axis index (HPA);
  * CT scan image analysis (using preoperative cancer staging and restaging chest and abdomen CT scans) performing automated imaging segmentation using Data Analysis Facilitation Suite (DAFS) by Voronoi Health Analytics, Inc. (https://www.voronoihealthanalytics.com/).
* Overall activity of the autonomic nervous system and heart rate variability through photoplethysmography (PPG) stress flow test. This exam allows the study and direct monitoring of all functions of the autonomic nervous system and the related process of biofeedback.
* Patient reported outcome questionnaires to measure health related quality of life and patient engagement. The following questionnaires will be administered

  * Patient reported outcome measurement information system (PROMIS)29+2, a validated questionnaire designed to measure self-reported physical, mental and social health and wellbeing.
  * Duke activity status index (DASI), a brief questionnaire designed to assess physical function by answering whether they are able to perform 12 listed activities of various intensity (i.e., ambulation, household tasks and leisure activities).
  * EORTC QLQ C30, a generic core questionnaire that measures health-related quality of life in patients with any cancer.
  * EORTC QLQ PAN-26, the pancreatic cancer module that supplements the EORTC QLQ-C30.
  * - Medically unexplained symptoms (MUS) questionnaire investigates the presence of vague symptoms to describe a cluster of manifestations such us chronic fatigue, sleep or appetite disorders, irritable bowel or constipation, tone or mood disorders, non-specific pain syndromes which are sometimes underestimated.
  * Patient activation measures (PAM)-13, a 13-item questionnaire measuring patients' self-reported knowledge, motivation, and skills for self-management.
  * Hospital Anxiety and Depression Scale (HADS) questionnaire to measure anxiety and depression.
* Blood sample analysis of circulating cytokines, chemokines, interferons, colony stimulating factors, main hormones involved in metabolic homeostasis and cancer cachexia.

Four weeks after baseline assessment, on the day before surgery (T1), all patients will repeat all evaluations previously performed at T0.

STUDY INTERVENTION Included patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation), which will receive prehabilitation, or to the control group, which will receive no prehabilitation. Patients in the control group will be treated according to usual standard of care and will be given informative material regarding healthy lifestyle and how to best prepare for surgery.

The intervention will consist of a multimodal prehabilitation, a 4-week long preoperative intervention including exercise training, nutritional therapy and anxiety reducing techniques, aimed at preventing or attenuating surgery-driven functional decline as described in the arms and intervention section.

VISITS AND FOLLOW-UP:

Throughout patient hospital stay, postoperative outcomes including complications, will be recorded. After discharge, patients will be followed-up as routine care by phone calls from a nurse navigator.

At 30 days (T2), 60 (T3) and 90 days (T4) after surgery, patient recovery will be re-evaluated during scheduled outpatient visits. Patients will be assessed for:

* Functional capacity by the 6MWT and other physical performance tests including TUG, gait speed assessment and handgrip strength test.
* Nutritional status by measurement of anthropometric parameters including body weight (kg), height (cm), and body mass index (kg/m2)
* Body composition by multi-frequency bioelectrical impedance vector analysis (BIVA)
* Health related quality of life through patient reported outcome questionnaires

STATISTICAL METHODS:

The analysis will be conducted on intention to treat basis. Continuous data will be presented as medians (interquartile range) or means (standard deviation); categorical data as absolute values and percentages. Dichotomous data will be compared by two tailed chi-square test or Fisher's exact test. Continuous measurements will be compared between groups using the Mann-Whitney U test or T-Student test for normally distributed data.

Baseline characteristics of the two groups will be reported in order to confirm the adequacy of the randomization process.

CCI will be described as the mean plus the standard deviation (SD) or median plus interquartile range (IQR), depending on its distribution. To analyze the difference in terms of CCI between groups t-student Test will be adopted in case of normal distribution, otherwise Mann-Whitney U test will be used.

6MWT as a functional capacity measure is a continuous variable. This data will be described as means, plus SD, at each time point. To accommodate the repeat measurements for individuals, a generalized linear mixed model will be used to compare results from both arms.

Pre-planned subgroup analysis in patients with higher risk features at enrollment (e.g., malnourished, sarcopenic obese, low physical function, frail) will also be performed to evaluate the effectiveness of prehabilitation in this population. Statistical analysis will be performed using STATA® version 16 software.

SAMPLE SIZE:

The size of the sample was calculated on the basis of the primary aim of the study: the reduction of postoperative complications as determined with the CCI score at 90 days after surgery. In our preliminary data on PDAC surgical population, the mean (SD) CCI is 21.0 (SD 16), and the target reduction is 30%. An alpha of 0.05 and power of 0.80 (two-sided test) was used. Expecting a dropout rate of 10%, 113 patients are needed in each arm for an overall sample of 226 patients.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Indication for curative resection for pancreatic or periampullary cancer
* Signed Informed consent

Exclusion Criteria:

* Metastatic or unresectable disease found preoperatively
* Comorbidities contraindicating prehabilitation regimen (exercise and nutritional intervention) such as orthopedic, cognitive disabilities, chronic renal failure (dialysis or creatinine \>250 mmol)
* ASA score 4-5
* Pregnancy
* Illiteracy (inability to read and understand Italian language)

Primary outcomes:
measure: Comprehensive Complication Index (CCI)
timeFrame: 90 days after surgery
measure: Functional capacity
timeFrame: One day before surgery; 30 days after surgery; 60 days after surgery; 90 days after surgery
measure: Pro-inflammatory cytokines
timeFrame: One day before surgery
measure: Cancer cachexia related factors
timeFrame: One day before surgery
Secondary outcomes:
measure: Time to patient functional recovery (TFR)
timeFrame: 90 days after surgery
measure: Lenght of stay (LOS)
timeFrame: 90 days after surgery
measure: Bioimpedance analysis (BIA) derived body composition
timeFrame: One day before surgery; 30 days after surgery; 60 days after surgery; 90 days after surgery
measure: Computed tomography derived body composition
timeFrame: One day before surgery.
measure: Generic health-related quality of life
timeFrame: One day before surgery; 30 days after surgery; 60 days after surgery; 90 days after surgery
measure: Disease-specific health-related quality of life
timeFrame: One day before surgery; 30 days after surgery; 60 days after surgery; 90 days after surgery
Other outcomes:
Locations:
city: Milan
country: Italy
facility: San Raffaele Hospital
state: Lombardia
Study officials:
affiliation: San Raffaele Hospital
name: Massimo Falconi, MD
role: STUDY_CHAIR
References:
citation: Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0.
citation: Lambert JE, Hayes LD, Keegan TJ, Subar DA, Gaffney CJ. The Impact of Prehabilitation on Patient Outcomes in Hepatobiliary, Colorectal, and Upper Gastrointestinal Cancer Surgery: A PRISMA-Accordant Meta-analysis. Ann Surg. 2021 Jul 1;274(1):70-77. doi: 10.1097/SLA.0000000000004527.
citation: Pecorelli N, Guarneri G, Vallorani A, Limongi C, Licinio AW, Di Salvo F, Tamburrino D, Partelli S, Crippa S, Falconi M. Validation of the PROMIS-29 Questionnaire as a Measure of Recovery After Pancreatic Surgery. Ann Surg. 2023 Nov 1;278(5):732-739. doi: 10.1097/SLA.0000000000006020. Epub 2023 Jul 19.